[Pseudo-LE syndrome after treatment with Venopyronum dragees] (author's transl)
During the past three years a pseudo-LE syndrome (with antimitochondrial antibodies) was diagnosed in 14 patients. Information from the patients and their doctors disclosed that twelve of them had taken Venopyronum dragees over a period of two months to five years before onset of first symptoms. Two of the patients died of nonspecific myocarditis. Clinical investigations strongly suggest that the drug may have played a role in the pathogenesis of the pseudo-LE syndrome which is likely to take a severe course if, as in the two patients, the cardiovascular system is involved.
D000328:Adult; D001323:Autoantibodies / Q000032:analysis; D001327:Autoimmune Diseases / Q000139:chemically induced*; D003937:Diagnosis, Differential; D005260:Female; D005334:Fever; D005455:Fluorescent Antibody Technique; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D008928:Mitochondria / Q000276:immunology; D009205:Myocarditis / Q000139:chemically induced; D010493:Pericarditis / Q000139:chemically induced; D010653:Phenylbutazone / Q000031:analogs & derivatives; D010996:Pleural Effusion / Q000139:chemically induced; D010998:Pleurisy / Q000139:chemically induced; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects*; D013577:Syndrome; D013924:Thrombophlebitis / Q000188:drug therapy; D014648:Varicose Veins / Q000188:drug therapy
D001323:Autoantibodies; D011720:Pyrazoles; C010619:phenopyrazone; D010653:Phenylbutazone
Pseudo-le-syndrom nach einnahme eines venenpräparates (venopyronum-dragees